Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
Open Access
- 11 March 2014
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 110 (7), 1721-1726
- https://doi.org/10.1038/bjc.2014.126
Abstract
Retreatment with ipilimumab has been shown to re-establish disease control in some patients with disease progression. Here, we report the efficacy and safety of retreatment with ipilimumab 3 mg kg(-1) among patients participating in an expanded access programme in Italy.Patients who achieved disease control during induction therapy were retreated with ipilimumab upon progression (3 mg kg(-1) every 3 weeks for up to four doses), providing they had not experienced toxicity that precluded further dosing. Tumour assessments were conducted after retreatment, and patients were monitored throughout for adverse events.Of 855 patients treated with ipilimumab, 51 were retreated upon disease progression. Of these, 28 (55\%) regained disease control upon retreatment and 42\% were alive 2 years after the first induction dose of ipilimumab; median overall survival was 21 months. Eleven patients (22\%) had a treatment-related adverse event of any grade during retreatment. These were generally mild-to-moderate and resolved within a median of 4 days. No new types of toxicity were reported.For patients who meet predefined criteria, retreatment with ipilimumab is generally well tolerated and can translate into clinical benefit. This strategy should be compared with other therapeutic options in randomised controlled trialsKeywords
This publication has 33 references indexed in Scilit:
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisAnnals of Oncology, 2012
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic MelanomaClinical Cancer Research, 2012
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJournal of Translational Medicine, 2011
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnnals of Oncology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanomaInvestigational New Drugs, 2010
- Tumor immunoediting and immunosculpting pathways to cancer progressionSeminars in Cancer Biology, 2007
- CD8+ T‐cell memory in tumor immunology and immunotherapyImmunological Reviews, 2006
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006